A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)

Trial Profile

A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs GDC 0853 (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2017 Planned End Date changed from 10 Mar 2018 to 10 Apr 2018.
    • 23 May 2017 Planned primary completion date changed from 10 Mar 2018 to 10 Apr 2018.
    • 23 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top